drugset / Trial / NCT07225712
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of SEP-363856 (75 mg/day or 100 mg/day) administered for 52 weeks in adult participants with schizophrenia
Timeline
- Start
- 2025-12-22
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulotaront | Small molecule | 75 mg | — |
| Subject | Ulotaront | Small molecule | 100 mg | — |